Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003740 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab in Treating Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00003740: Completed Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003740 is a Phase 2 study of Prostate Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003740, a Phase 2 study of Prostate Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have prostate cancer that has not responded to hormone therapy.
Conditions Studied
Interventions
- BIOLOGICAL trastuzumab
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-10 |
| Est. Completion | 2002-09 |
| Phase | Phase 2 |
What the finished NCT00003740 record still lists
NCT00003740 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which trastuzumab is the first listed.
NCT00003740 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00003740 about?
NCT00003740 is a clinical study titled "Trastuzumab in Treating Patients With Prostate Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have prostate cancer that has not responded to hormone th...
What is the current status of trial NCT00003740?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-10. Estimated completion is 2002-09.
What conditions does trial NCT00003740 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00003740?
The interventions under investigation include: trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003740?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003740 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia